Three panelists representing the real estate, banking, and health care industries weighed in on innovation in Houston. Photo via Greater Houston Partnership/Facebook

Something has shifted in Houston, and businesses across industries — whether it be real estate, health care, or energy — are focused on innovation, emerging technologies, and the role of startups within the business community.

At the Greater Houston Partnership's annual Economic Outlook on December 5, three panelists from various industries gathered to discuss some of the biggest issues in Houston — from the multifamily real estate market to what the local workforce needs. The panel was moderated by Eddie Robinson, the morning news anchor for Houston Public Radio, and the panelists did weigh in a few issues affecting innovation.

Missed the talk? Here are a few overheard moments from the discussion.

"Houston allows you to do what you do. And you don't get that in other places."

Photo via Greater Houston Partnership/Facebook

Bradley R. Freels, chairman of Midway Cos. Freels says, while the city's been overshadowed by other Texas cities for innovation and tech — and even by its large oil and gas industry presence, the city is becoming a great place for startups. "This is a great place to do business because it's easy to get started in business here. I think it's just over shadowed to some degree," he says, adding later that, "the initiative around the innovation corridor is real."

"Houston is unique, in my opinion, in how open and welcoming it is."

Photo via Greater Houston Partnership/Facebook

— David Milich, CEO of UnitedHealthcare - Texas & Oklahoma. Building off the panelists point that Houston is a spirited, can-do city, Milich specifies that it's the collaboration between people in Houston that sets the city apart. "When we present ourselves with something to get done, we generally get it down."

"We're realizing that the economy is shifting. As we move forward in the 21st century, our entire workforce needs to be tech fluent."

Photo via Greater Houston Partnership/Facebook

Nataly Marks, managing director and region manager at JPMorgan Chase. When asked about jobs needed in Houston, Marks specified technology positions. Moreover, JPMorgan Chase is emphasizing getting the entire staff proficient in the latest tech resources.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”